# An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc)

> **NCT05626751** · PHASE2 · TERMINATED · sponsor: **Amgen** · enrollment: 174 (actual)

## Conditions studied

- Diffuse Cutaneous Systemic Sclerosis
- Sclerosis, Systemic

## Interventions

- **DRUG:** HZN-825

## Key facts

- **NCT ID:** NCT05626751
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-11-04
- **Primary completion:** 2025-02-24
- **Final completion:** 2025-02-24
- **Target enrollment:** 174 (ACTUAL)
- **Why stopped:** The study was not stopped due to safety reasons
- **Last updated:** 2026-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05626751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05626751, "An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05626751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*